Skip to main content

Table 1 Baseline characteristics of the cohort (n = 281)

From: Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Characteristics

Median (IQR) or number (%)

Age (years)

52 (47–59)

Gender

Male

female

211 (75.2%)

70 (24.8%)

Origin

Italy

Other Countries

264 (94.0%)

17 (6.0%)

Risk factor for HIV

Heterosexual contacts

MSM

IVDU

Other

129 (45.9%)

78 (27.8%)

72 (25.6%)

2 (0.7%)

Co-infection HCV

Yes

No

46 (16.5%)

235 (83.5%)

Time on ART (years)

10.2 (4.6–17.2)

Previous ART regimens (number)

3 (2–5)

Time with HIV-RNA < 50 copies/ml (months)

75 (33–122)

Baseline CD4 (cells/mcL)

669 (483–927)

Baseline CD8 (cells/mcL)

767 (532–1034)

CD4/CD8 ratio

0.93 (0.61–1.30)